Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
AK20
/
Obio Pharmaceutical
Welcome,
Profile
Billing
Logout
0 Diseases
0 Trials
0 Trials
3 News
|
|||||||||
AK20
/
Obio
Biomarker, Journal:
Bioimpedance Analysis for Predicting Outcomes of Complex Decongestive Therapy for Gynecological Cancer Related Lymphedema: A Feasibility Study.
(Pubmed Central) - Jul 10, 2020
These findings implied that BIA value could be one possible parameter to apply in treatment outcomes prediction, during the early stage of GCRL. Therefore, further large-scale prospective studies will be beneficial.